OLEMA PHARMACEUTICALS

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2023 18:00:40 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jan 2023 16:30:01 By Nasdaq GlobeNewswire

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:58 By Nasdaq GlobeNewswire

Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

07 Dec 2022 15:37:49 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)

21 Nov 2022 09:16:07 By Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Present at Upcoming Investor Conferences in November

01 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

26 Oct 2022 03:00:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

12 Oct 2022 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2022 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2022 17:01:48 By Nasdaq GlobeNewswire

Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 16:35:00 By Nasdaq GlobeNewswire

Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

09 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

04 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

21 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2022 16:30:00 By Nasdaq GlobeNewswire